Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 20/20 | 1.00 |
| ▸ | PRKACA | P17612 | 10/20 | 1.00 |
| ▸ | GSK3B | P49841 | 10/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 9/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 7/20 | 1.00 |
| ▸ | GSK3A | P49840 | 7/20 | 1.00 |
| ▸ | JAK3 | P52333 | 7/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 7/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 7/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 7/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 6/20 | 1.00 |
| ▸ | CLK2 | P49760 | 6/20 | 1.00 |
| ▸ | PRKX | P51817 | 6/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 6/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 6/20 | 1.00 |
| ▸ | JAK2 | O60674 | 5/20 | 1.00 |
| ▸ | AURKA | O14965 | 5/20 | 1.00 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666668 | 0.91 | CDC7 (0.83) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL27810055 | 0.88 | CDC7 (0.79) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL27788170 | 0.87 | CDC7 (0.78) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL4285130 | 0.87 | CDC7 (1.00) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL3676069 | 0.85 | CDC7 (1.00) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL3666010 | 0.84 | CDC7 (1.00) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL3640551 | 0.83 | CDC7 (1.00) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL3667857 | 0.83 | CDC7 (0.83) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL3668887 | 0.82 | PRKACA (0.77) | CDC7PRKACAGSK3BMAP4K4CLK4 | |
| SCHEMBL3635048 | 0.82 | CDC7 (0.86) | CDC7PRKACAGSK3BMAP4K4CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | claimed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | claimed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-3447045-B9 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-07-21 | — | — | EP | disclosed |
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | SCOHIA PHARMA, INC. (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-3447045-B1 | 1-(1-HYDROXY-2,3-DIHYDRO-1H-INDEN-5-YL)-UREA DERIVATIVES AND RELATED COMPOUNDS KCNQ 2-5 CHANNEL ACTIVATORS FOR TREATING DYSURIA | ONO PHARMACEUTICAL CO (JP) | 2021-03-03 | — | — | EP | disclosed |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10570093-B2 | — | — | 2020-02-25 | — | — | US | disclosed |
| US-9163007-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8648069-B2 | 5-substituted indazoles as kinase inhibitors | ABBVIE INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | GLP1R, GPR119, GPR65 | CDC7 3762/4885PRKACA 3643/4885GSK3B 3993/4885 |
| US-20140343066-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | CDC7 8/4885PRKACA 178/4885GSK3B 1/4885 |
| US-20090203690-A1 | 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | GSK3B, GSK3A, PIM3 | CDC7 8/4885PRKACA 178/4885GSK3B 1/4885 |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | CDC7 2928/4885PRKACA 1414/4885GSK3B 3724/4885 |
| US-10570093-B2 | — | KCNQ5, KCNQ2, KCNQ1 | CDC7 3396/4885PRKACA 3898/4885GSK3B 3961/4885 |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | CDC7 291/4885PRKACA 768/4885GSK3B 1816/4885 |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | CDC7 2234/4885PRKACA 1779/4885GSK3B 3959/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | CDC7 2234/4885PRKACA 1779/4885GSK3B 3959/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | CDC7 2928/4885PRKACA 1414/4885GSK3B 3724/4885 |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GLP1R, GPR119, GPR65 | CDC7 3762/4885PRKACA 3643/4885GSK3B 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.